Application of a novel inhibitor of human CD59 for the enhancement of complement-dependent cytolysis on cancer cells

Cellular and Molecular Immunology

Volumn 8, Issue 2, 2011, Pages 157-163

  You, Tao ^a,b,c   Hu, Weiguo ^b,c   Ge, Xiaowen ^b   Shen, Jingnan ^a   Qin, Xuebin ^b,c  

^a SUN YAT SEN UNIVERSITY   (China)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

CD59; complement; lymphoma; multiple myeloma; rituximab

Indexed keywords

CD59 ANTIGEN; RECOMBINANT INTERMEDILYSIN DOMAIN 4; RECOMBINANT PROTEIN; RITUXIMAB; UNCLASSIFIED DRUG;

CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HUMAN CELL; LYMPHOMA; MULTIPLE MYELOMA; OSTEOSARCOMA; REVIEW; TUMOR CELL DESTRUCTION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD24; ANTIGENS, CD59; BACTERIOCINS; CELL LINE, TUMOR; CELL MEMBRANE; COMPLEMENT SYSTEM PROTEINS; CYTOTOXICITY, IMMUNOLOGIC; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LYMPHOMA; MULTIPLE MYELOMA; NEOPLASMS; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS;

EID: 79952399487     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2010.35     Document Type: Review

References (45)

1. Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007; 44: 3823-3837. (Pubitemid 47332625)
2. Villamor N, Montserrat E, Colomer D. Mechanism of action and resistance to monoclonal antibody therapy. Semin Oncol 2003; 30: 424-433. (Pubitemid 36999684)
3. Zhou X, Hu W, Qin X. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy. Oncologist 2008; 13: 954-966.
4. Morgan BP, Harris CL Complement Regulatory Proteins. London: Academic Press, 1999.
5. Hu W, Yu Q, Hu N, Byrd D, Amet T, Shikuma C et al. Ahigh- affinityinhibitorof human CD59 enhancescomplement-mediatedvirolysisof HIV-1: implicationsfortreatment of HIV-1/AIDS. J Immunol 2010; 184: 359-368.
6. Yu Q, Yu R, Qin X. Thegoodandevil of complementactivation in HIV-1 infection. Cell Mol Immunol 2010; in press.
7. Juhl H, Melmig F, Baltzer K, Kalthoff H, Hennebruns D, Kremer B. Frequent expression of complement resistance factors CD46, CD55, and CD59 on gastrointestinal cancer cells limits thetherapeutic potential of monoclonal antibody 17-1A. J Surg Oncol 1997; 64: 222-230. (Pubitemid 27157412)
8. Bjorge L, Hakulinen J, Wahlstrom T, Matre R, Meri S. Complement- regulatoryproteins in ovarian malignancies. Int J Cancer 1997; 70: 14-25.
9. Jarvis GA, Li J, Hakulinen J, Brady KA, Nordling S, Dahiya R et al. Expression and function of the complement membrane attack complex inhibitor protectin (CD59) in human prostatecancer. Int J Cancer 1997; 71: 1049-1055. (Pubitemid 27252889)
10. Coral S, Fonsatti E, Sigalotti L, de Nardo C, Visintin A, Nardi G et al. Overexpression of protectin (CD59) down-modulates the susceptibility of human melanoma cells to homologous complement. J Cell Physiol 2000; 185: 317-323.
11. Fonsatti E, Altomonte M, Coral S, deNardo C, Lamaj E, Sigalotti L et al. Emergingrole of protectin (CD59) in humoral immunotherapyof solid malignancies. Clin Ter 2000; 151:187-193.
12. Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000; 95: 3900-3908. (Pubitemid 30412866)
13. Harjunpaa A, Junnikkala S, Meri S. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand J Immunol 2000; 51: 634-641. (Pubitemid 30353375)
14. Golay J, Lazzari M, Facchinetti V, Bernasconi S, Borleri G, Barbui T et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocyticleukemia:further regulationbyCD55andCD59. Blood 2001; 98:3383-3389.
15. Takei K, Yamazaki T, Sawada U, Ishizuka H, Aizawa S. Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines. Leuk Res 2006; 30: 625-631. (Pubitemid 43374591)
16. Bjorge L, Stoiber H, Dierich MP, Meri S. Minimal residualdiseaseinovariancanceras atargetforcomplement-mediated mAbimmunotherapy. Scand J Immunol 2006; 63: 355-364.
17. Ziller F, Macor P, Bulla R, Sblattero D, Marzari R, Tedesco F. Controllingcomplement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59. Eur J Immunol 2005; 35: 2175-2183. (Pubitemid 41015056)
18. Macor P, Piovan E, Zorzet S, Tripodo C, Marzari R, Amadori A et al. Neutralizinghuman antibodiesagainstCD55 and CD59targetedto lymphoma cells in vivopotentiatethe therapeuticeffectof Rituximab. Mol Immunol 2007; 44: 212.
19. Dalle S, Dupire S, Brunet-Manquat S, Reslan L, Plesa A, Dumontet C. In vivomodel of follicular lymphoma resistantto rituximab. Clin Cancer Res 2009; 15: 851-857.
20. Hagenbeek A, Gadeberg O, Johnson P, Pedersen LM, Walewski J, Hellmann A et al. Firstclinical useof ofatumumab, anovel fullyhumananti-CD20monoclonal antibody in relapsedor refractoryfollicular lymphoma: resultsof a phase 1/2 trial. Blood 2008; 111: 5486-5495.
21. Castillo J, Milani C, Mendez-Allwood D. Ofatumumab, asecond- generationanti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders. Exp Opin Invest Drugs 2009; 18: 491-500.
22. Maddocks KJ, Lin TS. Update in the management of chronic lymphocytic leukemia. J Hematol Oncol 2009; 2: 29.
23. Fishelson Z, Donin N, Zell S, Schultz S, Kirschfink M. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (m C R Ps) in tumors. Mol Immunol 2003; 40: 109-123. (Pubitemid 36959821)
24. Bonavida B. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene 2007; 26: 3629-3636. (Pubitemid 46842700)
25. Zhao XJ, Zhao J, Zhou Q, Sims PJ. Identityof theresidues responsibleforthespecies-restricted complement inhibitoryfunction of human CD59. J Biol Chem 1998; 273: 10665-10671. (Pubitemid 28227680)
26. Bodian DL, Davis SJ, Morgan BP, Rushmere NK. Mutational analysisof theactivesite and antibody epitopes of the complement-inhibitory glycoprotein, CD59. J Exp Med 1997;185:507-516. (Pubitemid 27078369)
27. Husler T, Lockert DH, Sims PJ. Roleof adisulfide-bonded peptide loopwithin human complement C9 in the species-selectivity of complement inhibitor CD59. Biochemistry 1995; 35: 3263-3269.
28. Huang Y, Fedarovich A, Tomlinson S, Davies C Crystal structure of CD59: implications for molecular recognition of the complement proteins C8 and C9 in the membrane-attackcomplex. Acta Crystallogr D Biol Crystallogr 2007; 63: 714-721. (Pubitemid 46787696)
29. Huang Y, Qiao F, Abagyan R, Hazard S, Tomlinson S. Definingthe CD59-C9 binding interaction. J Biol Chem 2006; 281: 27398-27404.
30. Giddings KS, Zhao J, Sims PJ, Tweten RK. Human CD59 is a receptor for the cholesterol-dependent cytolysin intermedilysin. Nat Struct Mol Biol 2004; 11: 1173-1178.
31. Hu W, Ferris SP, Tweten RK, Wu G, Radaeva S, Gao B et al. Rapidconditionaltargeted ablation of cells expressing human CD59 in transgenic mice by intermedilysin. Nat Med 2008; 14: 98-103.
32. La Chapelle S, Tweten RK, Hotze EM. Intermedilysin-receptor interactions during assembly of the pore complex: assembly intermediates increase host cell susceptibility to complement-mediated lysis. J Biol Chem 2009; 284: 12719-12726.
33. Tweten RK. Cholesterol-dependent cytolysins, a family of versatile pore-forming toxins. Infect Immun 2005; 73: 6199-6209. (Pubitemid 41368781)
34. Hughes TR, Ross KS, Cowan GJ, Sivasankar B, Harris CL, Mitchell TJ et al. Identification of the high affinity binding site in the Streptococcus intermedius toxin intermedilysin for its membrane receptor, the human complement regulator CD59. Mol Immunol 2009; 46: 1561-1567.
35. Kapoor P, Greipp PT, Morice WG, Rajkumar SV, Witzig TE, Greipp PR. Anti-CD20 monoclonalantibodytherapyinmultiplemyeloma. Br J Haematol 2008; 141: 135-148.
36. Treon SP, Mitsiades C, Mitsiades N, Young G, Doss D, Schlossman R et al. Tumor cell expressionof CD59 isassociated with resistancetoCD20serotherapyin patientswith B-cell malignancies. J Immunother 2001; 24: 263-271. (Pubitemid 32479718)
37. Kolb EA, Gorlick R. Development of IGF-IR inhibitors in pediatric sarcomas. Curr Oncol Rep 2009; 11:307-313.
38. Loeb DM. Istherea rolefor immunotherapyinosteosarcoma? Cancer Treat Res 2010; 152: 447-457.
39. Macor P, Tripodo C, Zorzet S, Piovan E, Bossi F, Marzari R et al. In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. Cancer Res 2007; 67: 10556-10563. (Pubitemid 350070832)
40. Donev RM, Gray LC, Sivasankar B, Hughes TR, van den Berg CW, Morgan BP. Modulation of CD59 expression by restrictive silencer factor-derived peptides in cancer immunotherapyfor neuroblastoma. Cancer Res 2008; 68: 5979-5987.
41. Zhao WP, Zhu B, Duan YZ, Chen ZT. Neutralizationof complement regulatoryproteins CD55 and CD59 augments therapeutic effect of herceptin against lung carcinoma cells. Oncol Rep 2009; 21: 1405-1411.
42. Shi XX, Zhang B, Zang JL, Wang GY, Gao MH. CD59 silencing viaretrovirus-mediated RNA interferenceenhanced complement-mediated cell damage in ovary cancer. Cell Mol Immunol 2009; 6: 61-66.
43. Treon SP, Raje N, Anderson KC. Immunotherapeutic strategies for the treatment of plasma cell malignancies. Semin Oncol 2000; 27: 598-613.
44. Treon SP, Anderson KC. The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders. Semin Oncol 2000; 27: 79-85. (Pubitemid 32164599)
45. Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year ex-perience in 789 patientstreatedat asingle institution. Cancer 2006; 106: 1154-1161.